A detailed history of Quadrant Capital Group LLC transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Quadrant Capital Group LLC holds 31 shares of HCM stock, worth $538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31
Previous 31 -0.0%
Holding current value
$538
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$7.65 - $15.51 $3,649 - $7,398
-477 Reduced 93.9%
31 $0
Q3 2022

Nov 10, 2022

BUY
$8.63 - $15.52 $4,384 - $7,884
508 New
508 $5,000
Q2 2022

Aug 09, 2022

SELL
$8.59 - $20.77 $85 - $207
-10 Closed
0 $0
Q1 2022

May 06, 2022

SELL
$15.52 - $35.65 $17,009 - $39,072
-1,096 Reduced 99.1%
10 $0
Q4 2021

Feb 01, 2022

BUY
$28.89 - $35.33 $12,393 - $15,156
429 Added 63.37%
1,106 $39,000
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $1,497 - $1,803
42 Added 6.61%
677 $25,000
Q2 2021

Aug 09, 2021

BUY
$23.7 - $39.27 $10,451 - $17,318
441 Added 227.32%
635 $25,000
Q1 2021

May 12, 2021

BUY
$27.01 - $36.8 $1,755 - $2,392
65 Added 50.39%
194 $5,000
Q4 2020

Feb 16, 2021

BUY
$27.51 - $34.36 $220 - $274
8 Added 6.61%
129 $4,000
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $412 - $553
16 Added 15.24%
121 $4,000
Q2 2020

Aug 13, 2020

SELL
$17.65 - $28.05 $46,684 - $74,192
-2,645 Reduced 96.18%
105 $3,000
Q4 2019

Feb 03, 2020

BUY
$17.17 - $25.95 $47,217 - $71,362
2,750 New
2,750 $68,000
Q3 2019

Oct 24, 2019

SELL
$17.84 - $22.69 $78,513 - $99,858
-4,401 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$22.0 - $31.78 $49,764 - $71,886
2,262 Added 105.75%
4,401 $96,000
Q1 2019

Apr 29, 2019

BUY
$21.27 - $30.58 $2,190 - $3,149
103 Added 5.06%
2,139 $65,000
Q4 2018

Jan 17, 2019

BUY
$23.09 - $37.69 $47,011 - $76,736
2,036 New
2,036 $46,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.